Hirudin in haemodialysis.
The usability of recombinant hirudin as anticoagulant agent in haemodialysis was studied in nephrectomized dogs. To this end, we examined the capability of recombinant hirudin to penetrate the membranes of different capillary dialyzers used. Furthermore we investigated the pharmacokinetic behaviour of recombinant hirudin in nephrectomized dogs as well as its capability to prevent the activation of the clotting system and fibrin deposition during haemodialysis. The present results evidence the efficiency of recombinant hirudin in preventing thrombus formation in experimental haemodialysis and hence its suitability as anticoagulant in such extracorporeal circulation.
Bucha
E
E
Institute of Pharmacology and Toxicology, Medical Academy Erfurt, GDR.
Markwardt
F
F
Nowak
G
G
D000818:Animals; D001780:Blood Coagulation Tests; D001794:Blood Pressure / Q000187:drug effects; D004285:Dogs; D005260:Female; D005340:Fibrinogen / Q000187:drug effects; D006470:Hemorrhage / Q000517:prevention & control; D006493:Heparin; D006629:Hirudins / Q000097:blood / Q000494:pharmacology*; D008297:Male; D009392:Nephrectomy; D010976:Platelet Count / Q000187:drug effects; D011994:Recombinant Proteins / Q000097:blood / Q000494:pharmacology; D006435:Renal Dialysis
D006629:Hirudins; D011994:Recombinant Proteins; D005340:Fibrinogen; D006493:Heparin